Obesity drugs awarded as discovery of the year

The development of a type of anti-obesity drugs and the discovery that they can alleviate the health problems associated with it are for the magazine Science Advance to the Year 2023.

The scientific publication selects ten advances as highlights, including the discoveries of antibody therapies capable of slowing neurodegeneration in patients with Alzheimer’s disease or the development of weather forecasts assisted by artificial intelligence.

“Obesity meets its equal”, headlines Science the article dedicated to the breakthrough of the year and adds that “the best-selling weight loss drugs promise a wide range of health benefits.”

These are the GLP-1 group of drugs (glucagon-like peptide-1 agonists), developed almost 20 years ago to treat diabetes, but interest in treating obesity with them has recently emerged with “promising results”.

This year, several clinical trials showed that they reduced symptoms of heart failure and the risk of heart attacks and strokes, “providing the most compelling evidence to date that these drugs have important benefits in beyond weight loss itself.

The reach of these drugs is expanding “in ways their inventors could not have imagined” and trials are underway to determine why people with obesity and diabetes have reported less cravings for wine and tobacco during the treatment.

Application to Alzheimer’s disease and Parkinson’s disease

Others are trying these drugs to treat Alzheimer’s disease and Parkinson’s disease, in part because they have been shown to target brain inflammation. But like almost all medications, “these best-sellers have side effects and unknowns,” he says. Science. Among the first, possible intestinal problems or pancreatitis.

On the unknown side, he highlights the potential necessity of having to take them indefinitely and the concern of doctors for people who are not obese or overweight, but who use them to lose weight quickly. Not to mention the price, which can exceed a thousand dollars per month.

In any case, one thing “is clear”, which is that these therapies change not only the way of treating obesity, but also the way of understanding it as a chronic disease which finds its roots in biology and not in a simple failure of force. will do so, “and it can have as much impact as any medication.”

Leave a Comment